Allarity Therapeutics, Inc. Assets, Fair Value Adjustment
Allarity Therapeutics, Inc. (ALLR) reported Assets, Fair Value Adjustment of $65.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-14.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:AssetsFairValueAdjustment · last filed 2024-05-14
- Allarity Therapeutics, Inc. assets, fair value adjustment for the quarter ending 2024-03-31 was $65.00K, a 97.13% decline year-over-year.
- Allarity Therapeutics, Inc. assets, fair value adjustment for the quarter ending 2023-12-31 was -$3.08M.
- Allarity Therapeutics, Inc. assets, fair value adjustment for the quarter ending 2023-09-30 was $0.00.
- Allarity Therapeutics, Inc. assets, fair value adjustment for the quarter ending 2023-06-30 was $1.63M.
- Allarity Therapeutics, Inc. assets, fair value adjustment for fiscal 2023 was $820.00K, a 119.25% increase from fiscal 2022.
- Allarity Therapeutics, Inc. assets, fair value adjustment for fiscal 2022 was $374.00K.
| Period end | Assets, Fair Value Adjustment 3 month | Assets, Fair Value Adjustment 3 month as first filed | Assets, Fair Value Adjustment 6 month | Assets, Fair Value Adjustment 9 month | Assets, Fair Value Adjustment 12 month | Assets, Fair Value Adjustment 12 month as first filed |
|---|---|---|---|---|---|---|
| 2024-03-31 | $65.00K 10-Q · filed 2024-05-14 | -$3.01M derived: sum of 2 quarters · filed 2024-05-14 | -$3.01M derived: sum of 3 quarters · filed 2024-05-14 | -$1.38M derived: sum of 4 quarters · filed 2024-05-14 | ||
| 2023-12-31 | -$3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$3.08M derived: sum of 2 quarters · filed 2024-03-08 | -$1.45M derived: sum of 3 quarters · filed 2024-03-08 | $820.00K 10-K · filed 2024-03-08 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $1.63M derived: sum of 2 quarters · filed 2023-11-14 | $3.90M 10-Q · filed 2023-11-14 | $3.01M derived: sum of 4 quarters · filed 2024-05-14 | ||
| 2023-06-30 | $1.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $3.90M 10-Q · filed 2023-08-14 | $3.01M derived: sum of 3 quarters · filed 2024-05-14 | $2.75M derived: sum of 4 quarters · filed 2024-05-14 | ||
| 2023-03-31 | $2.27M 10-Q · filed 2024-05-14 | $565.00K 10-Q · filed 2023-05-11 | $1.38M derived: sum of 2 quarters · filed 2024-05-14 | $1.12M derived: sum of 3 quarters · filed 2024-05-14 | $374.00K derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | -$888.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$1.15M derived: sum of 2 quarters · filed 2024-03-08 | -$1.89M derived: sum of 3 quarters · filed 2024-03-08 | $374.00K 10-K · filed 2024-03-08 | ||
| 2022-09-30 | -$257.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$1.00M derived: sum of 2 quarters · filed 2022-11-14 | $1.26M 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | -$746.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-10-07 | $1.52M 10-Q · filed 2022-10-07 | ||||
| 2022-03-31 | $2.27M 10-Q · filed 2022-05-27 | |||||
| 2021-12-31 | $11.27M 10-Q · filed 2022-11-14 | $11.27K 10-Q · filed 2022-05-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |